Illumina reports Q1 2026 revenue up 4.8%, raises full-year guidance with $1.5B share buyback plan

Illumina announced Q1 2026 revenue of $1.09 billion, a 4.8% increase from the prior year, driven by strong demand for its NovaSeq X system. The company reported GAAP diluted EPS of $0.87 and non-GAAP EPS of $1.15, with operating margins improving. Illumina's board authorized an additional $1.5 billion share repurchase program, reflecting confidence in its growth strategy. For fiscal 2026, Illumina raised its revenue and EPS guidance, expecting $4.52-$4.62 billion in revenue and non-GAAP EPS of $5.15-$5.30, signaling optimism about expanding clinical applications and market demand.